Investing.com - Financial Markets Worldwide

Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01)

Published 28/07/2025, 13:00
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01)
RADX
13.83%

Radiopharm Theranostics Ltd (NASDAQ:RAD) announced Monday that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its product candidate Betabart (RV-01). The company disclosed the development in a statement to the Australian Securities Exchange, which was included in a filing with the U.S. Securities and Exchange Commission.

The IND approval allows Radiopharm Theranostics to begin clinical trials of Betabart (RV-01) in the United States. Details regarding the indication or the planned clinical program were not provided in the filing.

Radiopharm Theranostics is headquartered in Carlton, Victoria, Australia. The company’s principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053.

This article is based on a press release statement included in a SEC filing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.